You have read all your free articles, to continue reading subscribe to read the rest of this content.
Medivir and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir's nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China. Under the terms of the agreement, Medivir received an upfront paymeAlready a subscriber Login You have read all your free articles,…
The company has registered Dignitana S.r.l as a new entity in Italy, a wholly-owned subsidiary of Dignitana AB. The entity will function under the leadership of Dignitana AB and with this registration the company can now finalize contracts for the sale of 3 machines in Italy. “We are exciteAlready a subscriber…
The company announces that a Private Placement has been successfully placed, raising gross proceeds of NOK 230 million by allocating 5,750,000 shares at a subscription price of NOK 40.00 per Offer Share. The Private Placement received strong interest from existing shareholders and new investors. Already a subscriber Login You have…
Swedish EnginZyme has announced a Series A investment of 6.4 million EUR led by Sofinnova Partners. The funds will be used to accelerate the development of the company's technology platform and take its first internal production process to pilot, it states. A cell-free synthetic biology platformAlready a subscriber Login You…
